WinstonWınston
SStartrade Tech logo

SStartrade Tech

SSTT
51
Other Precious Metals · Basic Materials
Price
$0.00
+0.00 (+0.00%)
Market Cap
$19,922
Winston Score
51
Winston is curious
Mixed quality — meaningful strengths and weaknesses.

SStarTrade Tech, Inc. (SSTT) does not appear in my training data as a recognized public company. The ticker, name, and financial profile provided do not match any firm I can reliably identify. Writing specific details about products, customers, or competitive position without verified information would risk presenting fiction as fact.

To generate an accurate description, please provide one or more of the following: a brief business description, the company's main products or services, its primary customers or end markets, and the countries where it operates. With that context, a factual two-paragraph summary can be produced.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+21.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+12.4% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$13M/ year

Rising (+78% vs prior year)

6.4% of revenue

2.1x the sector average (3%)

R&D investment increasing — building for the future

Insider Activity

0.0%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$67M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

SStartrade Tech is a rare growth stock that's already generating positive cash flow while growing at 21%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.1% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 99.5M (2018) → 99.6M (2022)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
52.7%
Healthy — 52.7% gross margin
Operating Margin
16.0%
Healthy — 16.0% operating margin
ROCE
4.7%
Weak — 4.7% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+20.5%
Fast-growing sales (20.5% YoY)
EPS YoY
+63.4%
Earnings growing fast (63.4% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
55%
Weak — only 55% of profit becomes cash
FCF Margin
5.2%
Thin free cash flow (5.2%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
1.84
Elevated debt (1.84)
Interest Cover
7.16x
Adequate interest coverage (7.2x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
0.0x
Attractive valuation — P/E 0.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial